Physician profile
Chris Cherian
NPI 1285014159
$2,059.20
in general payments reported to CMS, 2019-2025
13 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 94% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $14.68 · 2023: $226 · 2024: $57.05 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,192 · Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,192.35 |
| Food and Beverage | $706.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,291.66 | 2025 | Iovera |
| Depuy Synthes Sales INC. | $340.04 | 2021-2025 | Healix Knotless Peek, Rigidloop, Monovisc |
| Bioventus LLC | $95.51 | 2021-2025 | Durolane, Xcell |
| Zimmer Biomet Holdings, INC. | $76.77 | 2021-2023 | Gel-One Cross-Linked Hyaluronate |
| Axogen | $59.72 | 2025 | |
| Davol INC. | $49.61 | 2025 | Channel Drain |
| Smith+Nephew, INC. | $48.91 | 2025 | Stravix Pl |
| Ebi, LLC | $20.40 | 2025 | Biomet Ebi Bone Healing System |
| Sanofi-Aventis U.S. LLC | $17.28 | 2021 | |
| Forte Bio-Pharma LLC | $15.33 | 2025 | Prolate, Nalocet, Tanlor |
| Pacira Therapeutics, INC. | $15.00 | 2021 | |
| Alfasigma USA, INC. | $14.68 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.